Title : Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.

Pub. Date : 2003 Apr

PMID : 12749662






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSION: This report shows that in selected patients with a severe form of neonatal Bartter"s syndrome, the new cyclooxygenase-2 inhibitor rofecoxib may control the clinical symptoms of hyperprostaglandin-E syndrome after ineffective indomethacin therapy. Indomethacin prostaglandin-endoperoxide synthase 2 Homo sapiens